<DOC>
	<DOCNO>NCT00833560</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness bortezomib combination standard regimen cyclophosphamide dexamethasone .</brief_summary>
	<brief_title>A Study Bortezomib , Cyclophosphamide , Dexamethasone Patients With Untreated Multiple Myeloma Planned High Dose Chemotherapy</brief_title>
	<detailed_description>This open-label ( participant investigator know treatment participant receive ) , prospective ( participant identify follow forward time outcome study ) , multi-centre , non-randomized ( participant assign different treatment group investigator ) study . The study conduct 2 part ( Part 1 Part 2 ) . Approximately 400 participant enrol ( 30 Part 1 370 Part 2 ) . In Part 1 optimum dose cyclophosphamide evaluate Part 2 select dose cyclophosphamide Part 1 administer . Part 2 include screen period maximum 14 day follow chemotherapy ( bortezomib , cyclophosphamide , dexamethasone ) maximum three 21-day cycle . Safety evaluate assessment adverse event , vital sign , physical examination , electrocardiogram , clinical laboratory test monitor throughout study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Cytologically histologically diagnosed multiple myeloma stage II/III Participants without precede cytostatic ( tend retard cellular activity multiplication ) treatment ( pretreatment radiation dexamethasone allow ) Agree use one contraception method define protocol Karnofsky performance status 60 percent Adequate laboratory test value Nonsecretory multiple myeloma Estimated life expectancy le 3 month History cancer ( except basal cell carcinoma ) last 5 year Peripheral neuropathy ( disorder peripheral nerve ) grade 2 Positive human immunodeficiency virus test active hepatitis B and/or hepatitis C Pregnant breastfeed female participant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Untreated multiple myeloma</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>VELCADE</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Remission therapy</keyword>
	<keyword>Induction therapy</keyword>
	<keyword>Stem Cell Transplantation</keyword>
</DOC>